Laura Brege

Filings by Laura Brege span 3 companies, the busiest being Pacira BioSciences, Inc., Acadia Pharmaceuticals Inc and Mirum Pharmaceuticals, Inc. Over a trading history stretching from 9 June 2021 to 10 June 2026, the count stands at 19 filings.

On the open market, the record shows 1 purchase worth €12k and 4 sales worth €613k. The net balance comes to €601k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 6 share grants and 8 option exercises.

The latest filing, published on 12 June 2026, reports a share grant in Pacira BioSciences, Inc. The most recent open-market purchase was published on 19 August 2024, 790 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.